Home > Insider Trading > Filing (0001209191-20-048864)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1080709	Arena Pharmaceuticals Inc	ARNA	Pharmaceutical Preparations (2834)	232908305

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1612551	Amit Munshi	C/O Arena Pharmaceuticals, Inc. 6154 Nancy Ridge Drive San Diego CA 92121	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-08-28	50,000	$15.50	57,750	No	4	M	Direct
Common Stock	Disposition	2020-08-28	50,000	$70.00	7,750	No	4	S	Direct
Common Stock	Acquisiton	2020-08-31	50,000	$15.50	57,750	No	4	M	Direct
Common Stock	Disposition	2020-08-31	50,000	$70.10	7,750	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2020-08-28	50,000	$0.00	50,000	$15.50
Common Stock	Employee Stock Option (right to buy)	Disposition	2020-08-31	50,000	$0.00	50,000	$15.50

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
288,139		2023-05-11	No	4	M	Direct
238,139		2023-05-11	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.
The options vested over four years, with 25% of the shares subject to the option vesting on May 11, 2017, and the remainder of the shares vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and were exercisable once vested.